Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 4.86
GRFS's Cash to Debt is ranked higher than
66% of the 1281 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. GRFS: 4.86 )
GRFS' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 4.86

Equity to Asset 0.31
GRFS's Equity to Asset is ranked higher than
57% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GRFS: 0.31 )
GRFS' s 10-Year Equity to Asset Range
Min: 0.28   Max: 0.37
Current: 0.31

0.28
0.37
Interest Coverage 3.07
GRFS's Interest Coverage is ranked higher than
50% of the 569 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GRFS: 3.07 )
GRFS' s 10-Year Interest Coverage Range
Min: 1.56   Max: 18.28
Current: 3.07

1.56
18.28
F-Score: 7
Z-Score: 2.51
M-Score: -2.23
WACC vs ROIC
2.05%
24.17%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 25.56
GRFS's Operating margin (%) is ranked higher than
94% of the 1049 Companies
in the Global Biotechnology industry.

( Industry Median: -83.68 vs. GRFS: 25.56 )
GRFS' s 10-Year Operating margin (%) Range
Min: 15.53   Max: 26.85
Current: 25.56

15.53
26.85
Net-margin (%) 14.01
GRFS's Net-margin (%) is ranked higher than
91% of the 1049 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. GRFS: 14.01 )
GRFS' s 10-Year Net-margin (%) Range
Min: 2.8   Max: 16.2
Current: 14.01

2.8
16.2
ROE (%) 20.02
GRFS's ROE (%) is ranked higher than
95% of the 1160 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. GRFS: 20.02 )
GRFS' s 10-Year ROE (%) Range
Min: 4.27   Max: 18.34
Current: 20.02

4.27
18.34
ROA (%) 6.38
GRFS's ROA (%) is ranked higher than
92% of the 1286 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. GRFS: 6.38 )
GRFS' s 10-Year ROA (%) Range
Min: 1.34   Max: 6.51
Current: 6.38

1.34
6.51
ROC (Joel Greenblatt) (%) 43.84
GRFS's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 1251 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. GRFS: 43.84 )
GRFS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 19.07   Max: 42.94
Current: 43.84

19.07
42.94
» GRFS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

GRFS Guru Trades in Q1 2014

Steven Cohen 456,098 sh (New)
Ron Baron 44,757 sh (+65.77%)
John Paulson 19,814,807 sh (-0.04%)
Mario Gabelli 29,777 sh (-0.67%)
Jim Simons 493,102 sh (-10.46%)
Caxton Associates 25,800 sh (-26.92%)
» More
Q2 2014

GRFS Guru Trades in Q2 2014

Caxton Associates 87,571 sh (+239.42%)
Jim Simons 526,802 sh (+6.83%)
Steven Cohen 112,300 sh (unchged)
John Paulson 19,605,181 sh (-1.06%)
Ron Baron 42,800 sh (-4.37%)
Mario Gabelli 25,177 sh (-15.45%)
» More
Q3 2014

GRFS Guru Trades in Q3 2014

Mario Gabelli 25,177 sh (unchged)
John Paulson 19,604,981 sh (unchged)
Ron Baron 42,800 sh (unchged)
Caxton Associates Sold Out
Jim Simons 365,002 sh (-30.71%)
Steven Cohen 22,700 sh (-79.79%)
» More
Q4 2014

GRFS Guru Trades in Q4 2014

Steven Cohen Sold Out
Mario Gabelli 23,968 sh (-4.80%)
John Paulson 17,792,140 sh (-9.25%)
Ron Baron 37,800 sh (-11.68%)
Jim Simons 93,102 sh (-74.49%)
» More
» Details

Insider Trades

Latest Guru Trades with GRFS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 33.40
GRFS's P/E(ttm) is ranked higher than
94% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GRFS: 33.40 )
GRFS' s 10-Year P/E(ttm) Range
Min: 17.7   Max: 95
Current: 33.4

17.7
95
Forward P/E 14.66
GRFS's Forward P/E is ranked higher than
98% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GRFS: 14.66 )
N/A
PE(NRI) 33.60
GRFS's PE(NRI) is ranked higher than
95% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GRFS: 33.60 )
GRFS' s 10-Year PE(NRI) Range
Min: 17.65   Max: 95
Current: 33.6

17.65
95
P/B 5.30
GRFS's P/B is ranked higher than
71% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 6.50 vs. GRFS: 5.30 )
GRFS' s 10-Year P/B Range
Min: 2.33   Max: 6.76
Current: 5.3

2.33
6.76
P/S 3.30
GRFS's P/S is ranked higher than
90% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 30.13 vs. GRFS: 3.30 )
GRFS' s 10-Year P/S Range
Min: 1.87   Max: 6.66
Current: 3.3

1.87
6.66
PFCF 22.10
GRFS's PFCF is ranked higher than
97% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GRFS: 22.10 )
GRFS' s 10-Year PFCF Range
Min: 16.28   Max: 1198.5
Current: 22.1

16.28
1198.5
POCF 15.73
GRFS's POCF is ranked higher than
97% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GRFS: 15.73 )
GRFS' s 10-Year POCF Range
Min: 11.45   Max: 381.13
Current: 15.73

11.45
381.13
EV-to-EBIT 16.38
GRFS's EV-to-EBIT is ranked higher than
97% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GRFS: 16.38 )
GRFS' s 10-Year EV-to-EBIT Range
Min: 11.7   Max: 47
Current: 16.38

11.7
47
PEG 1.18
GRFS's PEG is ranked higher than
99% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GRFS: 1.18 )
GRFS' s 10-Year PEG Range
Min: 0   Max: 2
Current: 1.18

0
2
Current Ratio 2.75
GRFS's Current Ratio is ranked higher than
66% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. GRFS: 2.75 )
GRFS' s 10-Year Current Ratio Range
Min: 2.19   Max: 3.26
Current: 2.75

2.19
3.26
Quick Ratio 1.59
GRFS's Quick Ratio is ranked higher than
60% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. GRFS: 1.59 )
GRFS' s 10-Year Quick Ratio Range
Min: 1.15   Max: 1.88
Current: 1.59

1.15
1.88
Days Inventory 235.28
GRFS's Days Inventory is ranked higher than
81% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GRFS: 235.28 )
GRFS' s 10-Year Days Inventory Range
Min: 268.2   Max: 713.13
Current: 235.28

268.2
713.13
Days Sales Outstanding 54.47
GRFS's Days Sales Outstanding is ranked higher than
85% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 112.01 vs. GRFS: 54.47 )
GRFS' s 10-Year Days Sales Outstanding Range
Min: 50.97   Max: 83.07
Current: 54.47

50.97
83.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.60
GRFS's Dividend Yield is ranked higher than
71% of the 201 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. GRFS: 1.60 )
GRFS' s 10-Year Dividend Yield Range
Min: 0.38   Max: 0.6
Current: 1.6

0.38
0.6
Dividend Payout 0.12
GRFS's Dividend Payout is ranked higher than
99% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GRFS: 0.12 )
GRFS' s 10-Year Dividend Payout Range
Min: 0.19   Max: 0.59
Current: 0.12

0.19
0.59
Yield on cost (5-Year) 1.60
GRFS's Yield on cost (5-Year) is ranked higher than
59% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 1.31 vs. GRFS: 1.60 )
GRFS' s 10-Year Yield on cost (5-Year) Range
Min: 0.38   Max: 0.6
Current: 1.6

0.38
0.6

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.20
GRFS's Price/Median PS Value is ranked higher than
83% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. GRFS: 1.20 )
GRFS' s 10-Year Price/Median PS Value Range
Min: 0.56   Max: 1.57
Current: 1.2

0.56
1.57
Earnings Yield (Greenblatt) 6.10
GRFS's Earnings Yield (Greenblatt) is ranked higher than
96% of the 1264 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. GRFS: 6.10 )
GRFS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.1   Max: 8.6
Current: 6.1

2.1
8.6

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:GIFLF.USA, GIKLY.USA, GRF.P.Spain, 0EM7.UK, GRF.Spain, GIFOF.USA, G0FB.Germany, OZT.Germany,
Grifols SA Was incorporated on June 22, 1987. It is a specialty biopharmaceutical company that develops, manufactures and distributes a broad range of plasma derivative products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. The Company operates in four business divisions: Bioscience, Diagnostic, Hospital and Raw Materials and Others. The Bioscience division includes activities relating to the manufacture of plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation and purification of plasma, and the sale and distribution of end products. The main plasma products it manufactures are IVIG, Factor VIII, A1PI and albumin. It also manufactures intramuscular immunoglobulins, ATIII, Factor IX and plasma thromboplastin component, or PTC. The Diagnostic division focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, including analytical instruments and reagents for diagnostics, as well as blood bank products. The Company concentrates its Diagnostic business in immunohematology and hemostasis product lines. The Diagnostic division's main customers are blood donation centers, clinical analysis laboratories and hospital immunohematology services. The Raw Material division provides raw materials for its intravenous therapy products like plastic and glass bottles, which the company purchases from various European suppliers. The Hospital division manufactures and installs products used by and in hospitals, such as parenteral solutions and enteral and parenteral nutritional fluids, which are sold almost exclusively in Spain and Portugal. It also includes products that the company do not manufacture. The Company operates in Latin America, in countries such as Mexico, Colombia, Argentina, Chile and Brazil. It sells Bioscience, Diagnostic and Hospital products to hospitals and clinics, GPOs, governments and other distributors globally. The Company's operations are subject to government authorities in the United States, at the federal, state and local level, and in other countries in which it operates.
» More Articles for GRFS

Headlines

Articles On GuruFocus.com
Gold-Focused Guru John Paulson Reports First Quarter Holdings May 22 2014 
Is Grifols Being Overlooked? Mar 19 2014 
John Paulson's Top Five Holdings Nov 20 2013 
John Paulson's Top Five Holdings Sep 12 2013 
Baron Funds Comments on Grifols SA Aug 30 2012 
Friday Value Overview Aug 19 2011 

More From Other Websites
Grifols to make a major equity investment in Alkahest Download (380.5 Kb) Mar 04 2015
Grifols to make a major equity investment in Alkahest Mar 04 2015
Grifols achieves a record net profit of 470.3 million euros with growth of 36.1% in 2014 Download... Feb 26 2015
4 Stocks Spiking on Unusual Volume: Novo Nordisk and More Jan 26 2015
Zacks Rank #5 Additions for Tuesday - Tale of the Tape Jan 20 2015
Grifols receives FDA approval for its new purification plant to produce Gamunex in Los Angeles... Jan 02 2015
Grifols introduces new 40-g IVIG vial size for GAMUNEX-C Dec 01 2014
3 Stocks Raising The Drugs Industry Higher Nov 04 2014
Grifols’ net profit increases by 26.9% to 339 million euros in the nine months to September 2014... Nov 04 2014
Investigating inhibitor development in patients with Hemophilia A Oct 17 2014
3 Stocks Boosting The Drugs Industry Higher Oct 16 2014
Grifols presents its GATRA scholarship program to promote research on antithrombin therapy Oct 15 2014
3 Health Services Stocks Moving The Industry Upward Aug 20 2014
3 Stocks Underperforming Today In The Health Services Industry Aug 12 2014
Many Leading Stocks Damaged As Market Tumbles Broadly Jul 31 2014
Stocks Work Off Session Lows; GoPro Bucks Weakness Jul 31 2014
Argentina Default Hits Futures; OpenText Spikes, Grifols Dives Jul 31 2014
Nasdaq Leads Late Gains; S&P 500, Dow Erase Losses Jul 11 2014
Grifols SA Stock Upgraded (GRFS) Jul 08 2014
Stock Futures Point Lower; GasLog, Grifols, Kapstone Lag Jul 08 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK